S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
NASDAQ:AMGN

Amgen Stock Competitors

$203.13
-4.71 (-2.27 %)
(As of 10/18/2021 04:00 PM ET)
Add
Compare
Today's Range
$202.45
$207.00
50-Day Range
$201.89
$231.20
52-Week Range
$200.47
$276.69
Volume2.81 million shs
Average Volume2.61 million shs
Market Capitalization$115.35 billion
P/E Ratio20.66
Dividend Yield3.39%
Beta0.68

Amgen (NASDAQ:AMGN) Vs. GILD, REGN, VRTX, BIIB, SGEN, ALNY, EXAS, RGEN, INCY, and BMRN

Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

Amgen vs.

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.

Amgen has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.

Regeneron Pharmaceuticals has a net margin of 50.11% compared to Amgen's net margin of 22.55%. Amgen's return on equity of 99.85% beat Regeneron Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen 22.55% 99.85% 15.16%
Regeneron Pharmaceuticals 50.11% 50.43% 33.56%

Amgen received 53 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 74.55% of users gave Amgen an outperform vote while only 68.36% of users gave Regeneron Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
AmgenOutperform Votes
1453
74.55%
Underperform Votes
496
25.45%
Regeneron PharmaceuticalsOutperform Votes
1400
68.36%
Underperform Votes
648
31.64%

74.7% of Amgen shares are owned by institutional investors. Comparatively, 82.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amgen presently has a consensus price target of $244.00, suggesting a potential upside of 20.12%. Regeneron Pharmaceuticals has a consensus price target of $698.50, suggesting a potential upside of 28.52%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
9 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.35
Regeneron Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.81

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$25.42 billion4.54$7.26 billion$16.6012.24
Regeneron Pharmaceuticals$8.50 billion6.84$3.51 billion$28.6618.96

In the previous week, Amgen had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 34 mentions for Amgen and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.32 beat Amgen's score of 0.06 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
5 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
9 Negative mention(s)
1 Very Negative mention(s)
Neutral
Regeneron Pharmaceuticals
3 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Regeneron Pharmaceuticals beats Amgen on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Amgen (NASDAQ:AMGN) vs. Its Competitors

TypeAmgenBiological Products IndustryMedical SectorNASDAQ Exchange
Dividend Yield3.39%2.16%1.97%2.54%
P/E Ratio20.6616.4332.3927.86
Net Margins22.55%-22,367.94%-3,876.14%-1,243.31%

Amgen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
3.3672 of 5 stars
$65.90
-2.6%
$75.60
-14.7%
+6.3%$82.63B$24.69B16.0713,600Analyst Revision
News Coverage
REGN
Regeneron Pharmaceuticals
2.9544 of 5 stars
$543.48
-1.8%
$698.50
-28.5%
-9.4%$58.13B$8.50B9.769,123
VRTX
Vertex Pharmaceuticals
2.7803 of 5 stars
$180.80
-0.5%
$266.61
-47.5%
-17.1%$46.90B$6.21B23.853,400Analyst Revision
News Coverage
BIIB
Biogen
2.5514 of 5 stars
$269.73
-4.2%
$379.65
-40.8%
-3.7%$40.20B$13.44B21.659,100Upcoming Earnings
Analyst Report
SGEN
Seagen
2.1231 of 5 stars
$171.97
-0.4%
$181.90
-5.8%
-14.4%$31.29B$2.18B52.752,092
ALNY
Alnylam Pharmaceuticals
2.0788 of 5 stars
$203.90
-2.3%
$177.31
-13.0%
+40.2%$24.23B$492.85M-26.861,453
EXAS
Exact Sciences
2.5125 of 5 stars
$95.83
-3.3%
$148.25
-54.7%
-7.2%$16.48B$1.49B-17.554,900
RGEN
Repligen
2.3831 of 5 stars
$263.78
-1.2%
$306.14
-16.1%
+54.5%$14.48B$366.26M147.361,128
INCY
Incyte
3.1371 of 5 stars
$64.58
-1.5%
$89.11
-38.0%
-28.7%$14.26B$2.67B42.491,773Analyst Report
Analyst Revision
BMRN
BioMarin Pharmaceutical
2.7152 of 5 stars
$73.92
-2.7%
$103.24
-39.7%
-6.7%$13.55B$1.86B17.233,059Analyst Revision
NVAX
Novavax
2.125 of 5 stars
$166.25
-2.6%
$249.60
-50.1%
+55.3%$12.38B$475.60M-12.13791
NBIX
Neurocrine Biosciences
2.4533 of 5 stars
$104.02
-0.5%
$119.46
-14.8%
+1.5%$9.83B$1.05B27.96845Analyst Revision
UTHR
United Therapeutics
2.4665 of 5 stars
$184.32
-1.5%
$224.38
-21.7%
+60.3%$8.28B$1.48B17.91950News Coverage
Positive News
EXEL
Exelixis
2.7399 of 5 stars
$21.31
-2.4%
$34.00
-59.5%
-8.3%$6.71B$987.54M73.48773Insider Selling
Analyst Revision
HALO
Halozyme Therapeutics
2.6188 of 5 stars
$37.11
-1.8%
$54.14
-45.9%
+29.1%$5.28B$267.59M23.79136
ALKS
Alkermes
1.8881 of 5 stars
$30.30
-4.5%
$29.80
-1.7%
+76.9%$4.89B$1.04B-75.752,245
IONS
Ionis Pharmaceuticals
1.9181 of 5 stars
$30.25
-16.0%
$52.19
-72.5%
-35.8%$4.27B$729M-7.82757News Coverage
Gap Down
High Trading Volume
ARNA
Arena Pharmaceuticals
2.5714 of 5 stars
$61.41
-2.4%
$97.46
-58.7%
-24.1%$3.75B$320,000.00-7.52363
FOLD
Amicus Therapeutics
2.0948 of 5 stars
$10.70
-3.6%
$18.36
-71.6%
-37.7%$2.85B$260.89M-11.15483Insider Selling
EBS
Emergent BioSolutions
2.3431 of 5 stars
$50.41
-0.6%
$96.50
-91.4%
-49.0%$2.71B$1.56B9.102,200
BCRX
BioCryst Pharmaceuticals
2.2375 of 5 stars
$14.92
-1.4%
$20.80
-39.4%
+288.0%$2.67B$17.81M-12.43246
OPK
OPKO Health
2.2731 of 5 stars
$3.70
-0.5%
$6.00
-62.2%
-13.9%$2.52B$1.44B33.645,269
MYGN
Myriad Genetics
1.5198 of 5 stars
$32.13
-1.2%
$25.33
-21.2%
+149.9%$2.51B$638.60M-23.452,700
CCXI
ChemoCentryx
2.3331 of 5 stars
$32.43
-6.3%
$72.63
-123.9%
-42.9%$2.27B$64.89M-18.32133
IRWD
Ironwood Pharmaceuticals
1.8515 of 5 stars
$13.41
-1.9%
$13.67
-1.9%
+29.3%$2.18B$389.52M4.30232
LGND
Ligand Pharmaceuticals
2.1598 of 5 stars
$128.57
-1.3%
$223.75
-74.0%
+32.1%$2.14B$186.42M46.422,018
CLDX
Celldex Therapeutics
2.3667 of 5 stars
$45.28
-2.0%
$59.00
-30.3%
+187.3%$2.10B$7.42M-27.11124
DVAX
Dynavax Technologies
2.0398 of 5 stars
$17.14
-1.2%
$21.00
-22.5%
+286.0%$1.97B$46.55M-65.92245Gap Up
CDXS
Codexis
1.8798 of 5 stars
$27.79
-1.9%
$31.33
-12.8%
+97.5%$1.80B$69.06M-75.11181Analyst Report
Insider Selling
MDGL
Madrigal Pharmaceuticals
2.4414 of 5 stars
$83.24
-3.5%
$169.78
-104.0%
-33.5%$1.38BN/A-5.7042
SGMO
Sangamo Therapeutics
1.7214 of 5 stars
$8.55
-2.3%
$23.00
-169.0%
-23.2%$1.24B$118.19M-9.00413
AGEN
Agenus
1.9931 of 5 stars
$5.09
-4.3%
$12.00
-135.8%
+16.2%$1.19B$88.17M-4.54359
IMGN
ImmunoGen
1.8731 of 5 stars
$5.78
-0.2%
$9.13
-57.9%
+0.5%$1.17B$132.30M-19.9379Gap Down
INVA
Innoviva
1.4831 of 5 stars
$16.23
-2.3%
$10.00
-38.4%
+63.3%$1.13B$336.79M6.545
MNKD
MannKind
2.1081 of 5 stars
$4.16
-22.4%
$6.20
-49.0%
+108.0%$1.04B$65.14M-11.89241News Coverage
Gap Down
High Trading Volume
VNDA
Vanda Pharmaceuticals
1.8664 of 5 stars
$18.06
-1.9%
$18.00
-0.3%
+67.4%$1.00B$248.17M31.14292News Coverage
LXRX
Lexicon Pharmaceuticals
2.2214 of 5 stars
$5.44
-13.2%
$12.00
-120.6%
+270.1%$785.94M$24M13.9578
CRIS
Curis
1.9664 of 5 stars
$7.43
-2.4%
$19.80
-166.5%
N/A$680.56M$10.84M-16.5128News Coverage
Gap Up
RIGL
Rigel Pharmaceuticals
1.9598 of 5 stars
$3.33
-1.5%
$11.00
-230.3%
+23.8%$568.93M$108.62M-66.60169
ICPT
Intercept Pharmaceuticals
2.3167 of 5 stars
$16.30
-3.2%
$33.00
-102.5%
-53.2%$541.18M$312.69M-3.17498
CLVS
Clovis Oncology
1.9648 of 5 stars
$4.19
-3.6%
$5.67
-35.2%
-30.1%$496.14M$164.52M-1.33N/A
VSTM
Verastem
1.9398 of 5 stars
$2.64
-4.5%
$6.33
-139.9%
+101.5%$477.20M$88.52M-11.48100Short Interest ↑
BOLT
Bolt Biotherapeutics
1.9664 of 5 stars
$12.52
-7.7%
$41.40
-230.7%
N/A$465.76M$230,000.00-0.5665Analyst Upgrade
Short Interest ↑
Negative News
GERN
Geron
1.7998 of 5 stars
$1.42
-0.7%
$7.00
-393.0%
-26.4%$455.25M$250,000.00-4.5854
ANAC
Arctos NorthStar Acquisition
1.1667 of 5 stars
$9.79
-0.0%
N/AN/A$387.01MN/A0.00N/A
ZIOP
ZIOPHARM Oncology
2.1031 of 5 stars
$1.64
-3.0%
$3.83
-133.7%
-39.5%$353.52M$150,000.00-3.90105
MTEM
Molecular Templates
2.5731 of 5 stars
$5.97
-6.2%
$14.50
-142.9%
-48.1%$335.17M$18.84M-3.26239Gap Down
SPPI
Spectrum Pharmaceuticals
2.1181 of 5 stars
$2.00
-2.0%
$7.33
-266.7%
-50.9%$328.14M$109.33M-1.63176
FBIO
Fortress Biotech
2.0914 of 5 stars
$3.04
-1.3%
$11.00
-261.8%
+10.1%$307.23M$45.60M-7.41111
XOMA
XOMA
1.8381 of 5 stars
$23.36
-10.4%
$49.00
-109.8%
+10.0%$264.23M$29.39M111.2410
This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.